ProCE Banner Activity

My Approach for Managing Patients With Progressive ALK-Positive NSCLC

Clinical Thought
What is the best approach for our patients with progressive ALK-positive NSCLC? Here I share my thoughts based on the latest available evidence on using ALK inhibitors in the setting of progressive disease.

Released: January 22, 2018

Share

Faculty

Lyudmila Bazhenova

Lyudmila Bazhenova, MD

Associate Clinical Professor of Medicine
Division of Hematology-Oncology
University of California, San Diego
Medical Director, UC San Diego Moores Cancer Center Infusion Center
San Diego, California

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Celgene TEXT Only

Genentech TEXT Only

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Takeda Oncology

Faculty Disclosure

Primary Author

Lyudmila Bazhenova, MD

Associate Clinical Professor of Medicine
Division of Hematology-Oncology
University of California, San Diego
Medical Director, UC San Diego Moores Cancer Center Infusion Center
San Diego, California

Lyudmila Bazhenova, MD, has disclosed that she has received consulting fees from AstraZeneca, Lilly, Novartis, and Takeda; has received funds for research support from BeyondSpring Pharmaceuticals; and holds ownership interests with Epic Sciences.